Research programme: erythropoietin gene expression inducers - Aventis/OSI

Drug Profile

Research programme: erythropoietin gene expression inducers - Aventis/OSI

Latest Information Update: 30 Oct 1998

Price : $50

At a glance

  • Originator Aventis; OSI Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 30 Oct 1998 Discontinued-Preclinical for Anaemia in USA (PO)
  • 28 May 1998 Preclinical development for Anaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top